软骨肉瘤的诊疗进展（英文）
|
摘要
软骨肉瘤是一种起源于软骨的恶性间充质肿瘤,是继骨肉瘤之后第二高发骨恶性肿瘤,好发于中青年。常见病变部位为中轴骨、骨盆和近端长骨,其不同的病理分型决定不同的治疗方法。本文旨在回顾软骨肉瘤相关文献,强调其早期诊断的重要性以便采取合适的治疗手段来改善预后。
Chondrosarcoma is a malignant mesenchymal tumor which originates from cartilaginous ranking as the second most common bone tumor following osteosarcoma.This tumor often can be observed in cartilage which is already present and quite specific to young and middle-aged people.It occurs more in the central skeleton,commonly arising from the pelvic girdle,vertebrae,and proximal long bones.It has several histologic types that determine various treatments.This review highlights the importance to consider the possibility of this tumor as an early diagnosis with proper surgical treatments to improve prognosis.
Chondrosarcoma is a malignant mesenchymal tumor which originates from cartilaginous ranking as the second most common bone tumor following osteosarcoma.This tumor often can be observed in cartilage which is already present and quite specific to young and middle-aged people.It occurs more in the central skeleton,commonly arising from the pelvic girdle,vertebrae,and proximal long bones.It has several histologic types that determine various treatments.This review highlights the importance to consider the possibility of this tumor as an early diagnosis with proper surgical treatments to improve prognosis.
引文
[1] Qian X.Updates in primary bone tumors:Current challenges and new opportunities in cytopathology[J].Surgical Pathology Clinics,2018,11(3):657-668.
[2] González DPJ,Lozano Calderón SA,Chebib I,et al.Intralesional versus wide resection of low-grade chondrosarcomas of the hand[J].Journal of Hand Surgery,2016,41(4):541-549.
[3] Karpik M,Reszec J.Low grade chondrosarcoma-epidemiology,diagnosis,treatment[J].Ortopedia,Traumatologia,Rehabilitacja,2018,20(1):65-70.
[4] Ferguson JL.Bone cancer:Diagnosis and treatment principles[J].American Family Physician,2018,98(4):205-213.
[5] Lin Y,Seger N,Chen Y,et al.hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality[J/OL].(2018-07-31)[2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180803/hTERT%20promoter%20mutations%20in%20chondrosarcomas%20associate%20.
[6] Murphey MD,Flemming DJ,Boyea SR,et al.Enchondroma versus chondrosarcoma in the appendicular skeleton:Differentiating features[J].Radiographics,1998,18(5):1213-1237.
[7] Bindiganavile S,Han I,Ji YY,et al.Long-term outcome of chondrosarcoma:A single institutional experience[J].Cancer Research & Treatment,2015,47(4):897-903.
[8] Italiano A,Mir O,Cioffi A,et al.Advanced chondrosarcomas:Role of chemotherapy and survival[J].Annals of Oncology,2013,24(11):2916-2922.
[9] Deckers C,Schreuder BHW,Hannink G,et al.Radiologic follow-up of untreated enchondroma and atypical cartilaginous tumors in the long bones[J].Journal of Surgical Oncology,2016,114(8):987.
[10] Evans HL,Ayala AG,Romsdahl MM.Prognostic factors in chondrosarcoma of bone:A clinicopathologic analysis with emphasis on histologic grading[J].Cancer,1977,40(2):818-831.
[11] Liu H.Chondrosarcoma in the mental foramen region of the mandible:A case report[J].Oncology Letters,2016,12(3):2081-2083.
[12] Matanic D,Kukuljan M,Grgurevic E,et al.Central type of chondrosarcoma with a fulminant course-a case report[J].Coll Antropol,2012,36(3):1037-1040.
[13] Mahajan AM,Ganvir S,Hazarey V,et al.Chondrosarcoma of the maxilla:A case report and review of literature[J].Journal of Oral & Maxillofacial Pathology,2013,17(2):269-273.
[14] Miura K,Kondo R,Kurai M,et al.Recurrence of juxtacortical chondrosarcoma arising on the rib[J].Gen Thorac Cardiovasc Surg,2016,64(3):170-173.
[15] Adimonye A.A rare and interesting case of a massive secondary spinal chondrosarcoma and review of the literature[J].Case Reports in Orthopedics,2015,2015:1-6.
[16] Holzapfel K,Regler J,Baum T,et al.Local staging of soft-tissue sarcoma:Emphasis on assessment of neurovascular encasement-value of MR imaging in 174 confirmed cases[J].Radiology,2015,275(2):501-509.
[17] Macpherson RE,Pratap S,Tyrrell H,et al.Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma[J].Clinical Sarcoma Research,2018,8(1):9.
[18] Horta M,Fernandes L,Borges A.Chondrosarcoma of the hyoid bone:An atypical site of a sarcoma of the head and the neck[J].Case Reports,2015,2015(354):575-581.
[19] Lee FY,Yu J,Chang SS,et al.Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone[J].Journal of Bone & Joint Surgery-American Volume,2004,86-A(12):2677-2685.
[20] Rakheja R,Makis W,Skamene S,et al.Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas:A retrospective review of 136 patients[J].Ajr Am J Roentgenol,2012,198(6):1409-1416.
[21] Fugl? HM,J?rgensen SM,Loft A,et al.The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma.A retrospective study of 89 patients[J].European Journal of Nuclear Medicine & Molecular Imaging,2012,39(9):1416-1424.
[22] Chauhan NP,Pai KM,Mutalik S,et al.A progressively enlarging swelling of the palate[J].Oral Surgery Oral Medicine Oral Pathology & Oral Radiology,2014,117(2):132-137.
[23] Gomes ACN,Silveira CRS,Paiva RGS,et al.Condrossarcoma em paciente com osteocondromatose múltipla:Relato de caso e revis?o da literatura Chondrosarcoma in a patient with multiple osteochondromatosis:a case report and review of the literature[J].Radiologia Brasileira,2006,39(6):449-451.
[24] Nota SPFT,Yvonne B,Schwab JH,et al.The identification of prognostic factors and survival statistics of conventional central chondrosarcoma[J].Sarcoma,2015,2015(1):59-72.
[25] Mavrogenis AF,Angelini A,Drago G,et al.Survival analysis of patients with chondrosarcomas of the pelvis[J].Journal of Surgical Oncology,2013,108(1):19-27.
[26] Mermerkaya MU,Bekmez S,Karaaslan F,et al.Intralesional curettage and cementation for low-grade chondrosarcoma of long bones:retrospective study and literature review[J].World Journal of Surgical Oncology,2014,12(1):1-5.
[27] Choong P,Chan LWM,Ngan SY,et al.Extracorporeal irradiation and reimplantation with total hip arthroplasty for periacetabular pelvic resections:A review of 9 cases[J].Sarcoma,2016,2016(397):1-7.
[28] Ma XL,Wang DB,Ma JX,et al.Custom-made prosthesis for reconstruction after radical resection for chondrosarcoma of manubrium[J].Orthopaedic Surgery,2018,10(3):272-275.
[29] Stevenson JD,Laitinen MK,Parry MC,et al.The role of surgical margins in chondrosarcoma[J].European Journal of Surgical Oncology,2018,44(9):1412-1418.
[30] Zoccali C,Baldi J,Attala D,et al.Intralesional vs extralesional procedures for low-grade central chondrosarcoma:A systematic review of the literature[J].Archives of Orthopaedic & Trauma Surgery,2018,138(7):1-9.
[31] Ivey JW,Bonakdar M,Kanitkar A,et al.Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment[J].Cancer Letters,2016,380(1):330-339.
[32] Ghedira D,Voissière A,Peyrode C,et al.Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma[J/OL].(2018-10-05) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180919/Structure-activity%20relationship%20study%20of%20hyp%20.
[33] Peterse EFP,Niessen B,Addie RD,et al.Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation[J].British Journal of Cancer,2018,118(8):1074.
[34] Kanbara K,Otsuki Y,Watanabe M,et al.GABAB receptor regulates proliferation in the high-grade chondrosarcoma cell line OUMS-27 via apoptotic pathways[J].Bmc Cancer,2018,18(1):263.
[35] Fukumoto S,Kanbara K.Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27[J].Acta Histochemica,2018,120(2):142-150.
[36] Yang X,Zhu G,Yang Z,et al.Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma[J/OL].(2018-03-01) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20181008/Expression%20of%20PD-L1%20PD-L2%20is%20.
[37] Mery B,Espenel S,Guy JB,et al.Biological aspects of chondrosarcoma:Leaps and hurdles[J/OL].(2018-03-22) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180803/Biological%20aspects%20of%20chondrosarcoma%20Leaps%20and%20hurdles%20.
[38] Fromm J,Klein A,Baur-Melnyk A,et al.Survival and prognostic factors in conventional central chondrosarcoma[J].BMC Cancer,2018,18(1):849.
[39] Nemecek E,Funovics PT,Hobusch GM,et al.C-reactive protein:An independent predictor for dedifferentiated chondrosarcoma[J].Journal of Orthopaedic Research,2018,36(10):2797-2801.
[2] González DPJ,Lozano Calderón SA,Chebib I,et al.Intralesional versus wide resection of low-grade chondrosarcomas of the hand[J].Journal of Hand Surgery,2016,41(4):541-549.
[3] Karpik M,Reszec J.Low grade chondrosarcoma-epidemiology,diagnosis,treatment[J].Ortopedia,Traumatologia,Rehabilitacja,2018,20(1):65-70.
[4] Ferguson JL.Bone cancer:Diagnosis and treatment principles[J].American Family Physician,2018,98(4):205-213.
[5] Lin Y,Seger N,Chen Y,et al.hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality[J/OL].(2018-07-31)[2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180803/hTERT%20promoter%20mutations%20in%20chondrosarcomas%20associate%20.
[6] Murphey MD,Flemming DJ,Boyea SR,et al.Enchondroma versus chondrosarcoma in the appendicular skeleton:Differentiating features[J].Radiographics,1998,18(5):1213-1237.
[7] Bindiganavile S,Han I,Ji YY,et al.Long-term outcome of chondrosarcoma:A single institutional experience[J].Cancer Research & Treatment,2015,47(4):897-903.
[8] Italiano A,Mir O,Cioffi A,et al.Advanced chondrosarcomas:Role of chemotherapy and survival[J].Annals of Oncology,2013,24(11):2916-2922.
[9] Deckers C,Schreuder BHW,Hannink G,et al.Radiologic follow-up of untreated enchondroma and atypical cartilaginous tumors in the long bones[J].Journal of Surgical Oncology,2016,114(8):987.
[10] Evans HL,Ayala AG,Romsdahl MM.Prognostic factors in chondrosarcoma of bone:A clinicopathologic analysis with emphasis on histologic grading[J].Cancer,1977,40(2):818-831.
[11] Liu H.Chondrosarcoma in the mental foramen region of the mandible:A case report[J].Oncology Letters,2016,12(3):2081-2083.
[12] Matanic D,Kukuljan M,Grgurevic E,et al.Central type of chondrosarcoma with a fulminant course-a case report[J].Coll Antropol,2012,36(3):1037-1040.
[13] Mahajan AM,Ganvir S,Hazarey V,et al.Chondrosarcoma of the maxilla:A case report and review of literature[J].Journal of Oral & Maxillofacial Pathology,2013,17(2):269-273.
[14] Miura K,Kondo R,Kurai M,et al.Recurrence of juxtacortical chondrosarcoma arising on the rib[J].Gen Thorac Cardiovasc Surg,2016,64(3):170-173.
[15] Adimonye A.A rare and interesting case of a massive secondary spinal chondrosarcoma and review of the literature[J].Case Reports in Orthopedics,2015,2015:1-6.
[16] Holzapfel K,Regler J,Baum T,et al.Local staging of soft-tissue sarcoma:Emphasis on assessment of neurovascular encasement-value of MR imaging in 174 confirmed cases[J].Radiology,2015,275(2):501-509.
[17] Macpherson RE,Pratap S,Tyrrell H,et al.Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma[J].Clinical Sarcoma Research,2018,8(1):9.
[18] Horta M,Fernandes L,Borges A.Chondrosarcoma of the hyoid bone:An atypical site of a sarcoma of the head and the neck[J].Case Reports,2015,2015(354):575-581.
[19] Lee FY,Yu J,Chang SS,et al.Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone[J].Journal of Bone & Joint Surgery-American Volume,2004,86-A(12):2677-2685.
[20] Rakheja R,Makis W,Skamene S,et al.Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas:A retrospective review of 136 patients[J].Ajr Am J Roentgenol,2012,198(6):1409-1416.
[21] Fugl? HM,J?rgensen SM,Loft A,et al.The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma.A retrospective study of 89 patients[J].European Journal of Nuclear Medicine & Molecular Imaging,2012,39(9):1416-1424.
[22] Chauhan NP,Pai KM,Mutalik S,et al.A progressively enlarging swelling of the palate[J].Oral Surgery Oral Medicine Oral Pathology & Oral Radiology,2014,117(2):132-137.
[23] Gomes ACN,Silveira CRS,Paiva RGS,et al.Condrossarcoma em paciente com osteocondromatose múltipla:Relato de caso e revis?o da literatura Chondrosarcoma in a patient with multiple osteochondromatosis:a case report and review of the literature[J].Radiologia Brasileira,2006,39(6):449-451.
[24] Nota SPFT,Yvonne B,Schwab JH,et al.The identification of prognostic factors and survival statistics of conventional central chondrosarcoma[J].Sarcoma,2015,2015(1):59-72.
[25] Mavrogenis AF,Angelini A,Drago G,et al.Survival analysis of patients with chondrosarcomas of the pelvis[J].Journal of Surgical Oncology,2013,108(1):19-27.
[26] Mermerkaya MU,Bekmez S,Karaaslan F,et al.Intralesional curettage and cementation for low-grade chondrosarcoma of long bones:retrospective study and literature review[J].World Journal of Surgical Oncology,2014,12(1):1-5.
[27] Choong P,Chan LWM,Ngan SY,et al.Extracorporeal irradiation and reimplantation with total hip arthroplasty for periacetabular pelvic resections:A review of 9 cases[J].Sarcoma,2016,2016(397):1-7.
[28] Ma XL,Wang DB,Ma JX,et al.Custom-made prosthesis for reconstruction after radical resection for chondrosarcoma of manubrium[J].Orthopaedic Surgery,2018,10(3):272-275.
[29] Stevenson JD,Laitinen MK,Parry MC,et al.The role of surgical margins in chondrosarcoma[J].European Journal of Surgical Oncology,2018,44(9):1412-1418.
[30] Zoccali C,Baldi J,Attala D,et al.Intralesional vs extralesional procedures for low-grade central chondrosarcoma:A systematic review of the literature[J].Archives of Orthopaedic & Trauma Surgery,2018,138(7):1-9.
[31] Ivey JW,Bonakdar M,Kanitkar A,et al.Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment[J].Cancer Letters,2016,380(1):330-339.
[32] Ghedira D,Voissière A,Peyrode C,et al.Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma[J/OL].(2018-10-05) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180919/Structure-activity%20relationship%20study%20of%20hyp%20.
[33] Peterse EFP,Niessen B,Addie RD,et al.Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation[J].British Journal of Cancer,2018,118(8):1074.
[34] Kanbara K,Otsuki Y,Watanabe M,et al.GABAB receptor regulates proliferation in the high-grade chondrosarcoma cell line OUMS-27 via apoptotic pathways[J].Bmc Cancer,2018,18(1):263.
[35] Fukumoto S,Kanbara K.Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27[J].Acta Histochemica,2018,120(2):142-150.
[36] Yang X,Zhu G,Yang Z,et al.Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma[J/OL].(2018-03-01) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20181008/Expression%20of%20PD-L1%20PD-L2%20is%20.
[37] Mery B,Espenel S,Guy JB,et al.Biological aspects of chondrosarcoma:Leaps and hurdles[J/OL].(2018-03-22) [2018-11-16].http://view.pubtsg.com:8080/enpdf/2018/20180803/Biological%20aspects%20of%20chondrosarcoma%20Leaps%20and%20hurdles%20.
[38] Fromm J,Klein A,Baur-Melnyk A,et al.Survival and prognostic factors in conventional central chondrosarcoma[J].BMC Cancer,2018,18(1):849.
[39] Nemecek E,Funovics PT,Hobusch GM,et al.C-reactive protein:An independent predictor for dedifferentiated chondrosarcoma[J].Journal of Orthopaedic Research,2018,36(10):2797-2801.